CSL New Zealand Fibrogammin factor XIII, Freeze-Dried 250 IU, powder for injection vial with 4 mL diluent ampoule

Описание товара

About CSL New Zealand Fibrogammin factor XIII, Freeze-Dried 250 IU, powder for injection vial with 4 mL diluent ampoule

CSL New Zealand Fibrogammin factor XIII, Freeze-Dried 250 IU, powder for injection vial with 4 mL diluent ampoule is a specialized medicinal product designed for clinical use. This preparation contains human coagulation factor XIII, which is essential for the stabilization of fibrin clots within the blood. The product is supplied as a freeze-dried powder contained in a glass vial, accompanied by a separate 4 mL ampoule of diluent required for reconstitution before administration. This medication is intended for professional healthcare settings where precise dosing and sterile preparation are strictly maintained. It serves as a replacement therapy for individuals requiring supplemental factor XIII to support normal blood coagulation processes. Always ensure the product is stored according to the specific temperature requirements provided on the packaging to maintain its integrity and efficacy until the time of use.

Key Benefits & Uses

• Provides essential human coagulation factor XIII for patients with identified deficiencies.
• Supports the stabilization of fibrin clots to assist in normal physiological blood clotting.
• Includes a convenient 4 mL diluent ampoule to facilitate accurate and sterile reconstitution of the freeze-dried powder.

Active Ingredient & Action

The active ingredient in this medication is human coagulation factor XIII. This protein plays a critical role in the final stages of the blood coagulation cascade by cross-linking fibrin strands, which strengthens the clot and makes it more resistant to premature breakdown.

Important Notes

This product must be administered under the direct supervision of a qualified medical professional. Patients should consult their healthcare provider regarding the appropriate administration technique and potential risks associated with the use of human-derived blood products. Do not use if the packaging is damaged or if the solution appears cloudy after reconstitution.